Sabine Bois
CEO since 2021 (employed by the company as CFO in 2014 and co-CEO since 2018).
Born 1980.
Education: MBA in Entrepreneurship and Finance, University of Wuppertal, Germany.
Background: Over 15 years of experience from the Biotech/Med-tech industry, among others from supporting the foundation of several successful start-ups within the research center and incubator “Caesar” in Bonn. Co-founding the biotech company Biosensor/SAW Instruments GmbH in 2007 (sold 2013).
Other current positions: –
Holdings in the Company (including related parties): 399,040 shares and 143,680 share options.
Lars Nordenskjöld
CFO since 2021.
Born 1959.
Education: Degree of Master of Science in Business and Administration, Stockholm School of Economics, Sweden.
Background: Extensive experience in financial leadership within rapidly expanding international and multicultural organizations within the Life Science, Healthcare & Care, and IT industries, among others as CFO at TFS Trial Form Support International AB, Deputy CEO and CFO at Svar Life Science, CFO at Ambea AB, and Group Controller at Intentia AB (publ).
Other current positions: LW Financial Management.
Holdings in the Company (including related parties): 57,480 share options, no shares.
Jozef Bartunek
Chief Medical Officer (CMO) since 2022.
Born 1963.
Education: MD and PhD Faculty of Medicine, Cormenius University in Bratislava, Slovak Republic. Clinical and research cardiology fellowships Cardiovascular Center Aalst, Belgium, Beth Israel Deaconess Medical Center, Boston, MA.
Background: Practicing cardiologist with more than 25 years of experience combining expertise in interventional cardiology and heart failure. Research and innovation track in biologic and device-based interventions in heart failure and structural heart disease. Published more than 300 peer-reviewed articles as well as serves in editorial boards of several cardiovascular journals.
Other current positions: Associate Director, Cardiovascular Centre, OLV Hospital, Aalst, Belgium.
Holdings in the Company (including related parties): –
Mathias Bouzereau
VP Global Marketing & Business Development since 2022.
Born 1971.
Education: Master of Business Administration from IMD Business School in Lausanne, Switzerland, a Master of Science in Computer Science from INSA Lyon, France, and the University of Nottingham, UK.
Background: 25 years of experience in the MedTech as well as High-Tech Solutions & Services Industry, bringing technology and business model innovation to market. Held several leadership positions in Europe and Latin America at Medtronic and Gemalto (now part of Thales), driving profitable growth in start-up, M&A and turnaround contexts.
Other current positions: –
Holdings in the Company (including related parties): –
Morwan Choli
VP Regulatory Affairs & Quality since 2023.
Born 1976.
Education: Ph.D in Physics from Julius-Maximilian University Wuerzburg and Scientific background in Magnetic Resonance Imaging in cooperation with Forschungszentrum für Magnet-Resonanz-Bayern e.V. (MRB e.V) , Kopfklinik at University Hospital Heidelberg and St. Judes Children’s Research Hospital in Memphis.
Background: Extensive experience in regulatory certification processes in cooperation with different EU Notified Bodies. Has acted in several management roles and been responsible for an implantable device certification department in Germany as well as an overall medical device testing and certification division in Japan and Asia, supporting global medical device manufacturers.
Other current positions: –
Holdings in the Company (including related parties): –
Jose de la Cortina
CCO since 2022
Born 1973.
Education: Science Degree in Medical Biology from Université du Québec in Trois-Rivières, Canada, and a Commerce Degree in International Business from Concordia University in Montreal, Canada.
Background: 23 years of experience in the industry at Baylis Medical as a critical contributor to the huge success story of Baylis Medical that was acquired by Boston Scientific for 1.75 B USD$, by driving commercialization into the USA, Japan, Europe, and many other regions.
Other current positions: –
Holdings in the Company (including related parties): –
Frank Dallmann
VP Research & Development since 2021.
Born 1969.
Education: Degree in Mechanical Engineering, Design and Product development from the Technical University in Dresden, Germany.
Background: 20 years of international experience in Research and Development of medical devices. Among other experiences as Head of Shoulder Development at Mathys Ltd. Bettlach in Germany and Switzerland.
Other current positions: –
Holdings in the Company (including related parties): –
Thomas Okke Frahm
VP IT since 2022.
Born 1972.
Education: Marketing Management, Copenhagen Business School, Denmark and studies at IMD Business School in Lausanne, Switzerland.
Background: 25 years of experience from IT strategy/transformation and from business development within the digital landscape. Previously similar roles within the Danish companies Vestas, Nilfisk, Chr. Hansen and Maersk.
Other current positions: –
Holdings in the Company (including related parties): –
Sakarias Lindell
VP People & Culture since 2022.
Born 1981.
Education: Management and Behavioral Science, Scandinavian International University, Sweden
Background: 20 years’ experience from Medtech in various positions within sales and supply chain. Site Manager of Occlutech International, Management Consultant at Performax, Area Sales Manager at Olympus, Abbot Vascular and coach for the Swedish National Gymnastics Team.
Other current positions: –
Holdings in the Company (including related parties): –
Luis Martin-Parras
VP Supply Chain & Manufacturing since June 2022 (employed as Managing Director Occlutech GmbH since 2016).
Born 1962.
Education: PhD Molecular Biology, Universidad Complutense de Madrid, Spain.
Background: Over 20 years of international experience in academic R&D environments and the Biotech/Medtech industry, with extensive experience in establishing, developing and leading company subsidiaries, R&D and supply chain operations and cross-functional teams.
Other current positions: –
Holdings in the Company (including related parties): 40,220 shares
Holdings as per March 31, 2022.
